N. Kruhlak

发表

Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products.

Naomi L Kruhlak, R Daniel Benz, Edwin J Matthews, 2007, Advanced drug delivery reviews.

Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.

N. Kruhlak, J. Contrera, R. Benz, 2004, Regulatory toxicology and pharmacology : RTP.

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints.

N. Kruhlak, J. Contrera, R. Benz, 2006, Regulatory toxicology and pharmacology : RTP.

In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software.

N. Kruhlak, J. Contrera, R. Benz, 2005, Regulatory toxicology and pharmacology : RTP.

Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data.

N. Kruhlak, J. Contrera, R. Benz, 2004, Current drug discovery technologies.

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods.

N. Kruhlak, J. Contrera, R. Benz, 2006, Regulatory toxicology and pharmacology : RTP.

Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science.

D. Strauss, Vikram Patel, N. Kruhlak, 2018 .

Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models.

Naomi L Kruhlak, R Daniel Benz, Edwin J Matthews, 2007, Regulatory toxicology and pharmacology : RTP.

Construction and application of (Q)SAR models to predict chemical‐induced in vitro chromosome aberrations

Lidiya Stavitskaya, Naomi L. Kruhlak, N. Kruhlak, 2018, Regulatory toxicology and pharmacology : RTP.

A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals.

Naomi L Kruhlak, Gilles Klopman, Edwin J Matthews, 2007, Regulatory toxicology and pharmacology : RTP.

Development of a Phospholipidosis Database and Predictive Quantitative Structure-Activity Relationship (QSAR) Models

Naomi L Kruhlak, Sydney S Choi, Joseph F Contrera, 2008, Toxicology mechanisms and methods.

Computational identification of a phospholipidosis toxicophore using (13)C and (15)N NMR-distance based fingerprints.

Svetoslav H. Slavov, N. Kruhlak, R. Beger, 2014, Bioorganic & medicinal chemistry.

Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking

Marlene T. Kim, Christopher R. Ellis, N. Kruhlak, 2018, PloS one.

Development of improved QSAR models for predicting the outcome of the in vivo micronucleus genetic toxicity assay.

K. Cross, Alexander Sedykh, N. Kruhlak, 2020, Regulatory toxicology and pharmacology : RTP.

Evaluating kratom alkaloids using PHASE

Marlene T. Kim, Christopher R. Ellis, D. Strauss, 2020, PloS one.

Syntheses, structures, and stabilities of [PPh(4)][WS(3)(SR)](R=(i)Bu,(i)Pr,(i)Bu, benzyl, allyl) and [PPh(4)][MoS(3)(S(t)Bu)].

N. Kruhlak, R. McDonald, M. Parvez, 2001, Inorganic chemistry.

(Q)SAR Modeling and Safety Assessment in Regulatory Review

R D Benz, N L Kruhlak, T. Colatsky, 2012, Clinical pharmacology and therapeutics.

Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.

Naomi L Kruhlak, R Daniel Benz, Edwin J Matthews, 2004, Current drug discovery technologies.

Translating New Science Into the Drug Review Process

David G. Strauss, Vikram Patel, Naomi Kruhlak, 2017, Therapeutic innovation & regulatory science.

Chemical Structure-Based and Toxicogenomic Models

Lidiya Stavitskaya, Jiri Aubrecht, Naomi L. Kruhlak, 2015 .

Testing computational toxicology models with phytochemicals.

Naomi L Kruhlak, R Daniel Benz, Luis G Valerio, 2010, Molecular nutrition & food research.

Genetic toxicology in silico protocol.

Raymond R Tice, Naomi L Kruhlak, Lidiya Stavitskaya, 2019, Regulatory toxicology and pharmacology : RTP.

In Silico Approaches In Carcinogenicity Hazard Assessment: Current Status and Future Needs.

Manuela Pavan, Jordi Mestres, Naomi L. Kruhlak, 2021, Computational toxicology.

New science, drug regulation, and emergent public health issues: The work of FDA’s division of applied regulatory science

D. Strauss, Zhihua Li, Wendy W Wu, 2023, Frontiers in Medicine.

Improving prediction of carcinogenicity to reduce, refine, and replace the use of experimental animals.

Lidiya Stavitskaya, Naomi Kruhlak, David Jacobson-Kram, 2015, Journal of the American Association for Laboratory Animal Science : JAALAS.

In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property Descriptors

Naomi L. Kruhlak, N. Kruhlak, J. Contrera, 2008, Toxicology mechanisms and methods.

In silico toxicology protocols.

Tudor I. Oprea, Naomi L Kruhlak, Lidiya Stavitskaya, 2018, Regulatory toxicology and pharmacology : RTP.

Understanding Genetic Toxicity Through Data Mining: The Process of Building Knowledge by Integrating Multiple Genetic Toxicity Databases

R Benigni, A M Richard, C Yang, 2008, Toxicology mechanisms and methods.

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?*

Naomi L Kruhlak, Lidiya Stavitskaya, Alexander Amberg, 2018, Mutagenesis.

A structural feature-based computational approach for toxicology predictions

Naomi L Kruhlak, Chihae Yang, Luis G Valerio, 2010, Expert opinion on drug metabolism & toxicology.

Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data.

Naomi L Kruhlak, Xiao Zhu, N. Kruhlak, 2014, Toxicology.

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.

Lidiya Stavitskaya, Alexander Amberg, Masamitsu Honma, 2016, Regulatory toxicology and pharmacology : RTP.

Assessing the Structural and Pharmacological Similarity of Newly Identified Drugs of Abuse to Controlled Substances Using Public Health Assessment via Structural Evaluation

Christopher R Ellis, Rebecca Racz, Naomi L Kruhlak, 2019, Clinical pharmacology and therapeutics.

Combined Use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows Software to Achieve High-Performance, High-Confidence, Mode of Action–Based Predictions of Chemical Carcinogenesis in Rodents

Naomi L Kruhlak, R Daniel Benz, Chihae Yang, 2008, Toxicology mechanisms and methods.

Establishing best practise in the application of expert review of mutagenicity under ICH M7.

Lidiya Stavitskaya, Alexander Amberg, Steve Gutsell, 2015, Regulatory toxicology and pharmacology : RTP.

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

B. Corrigan, Sue-Jane Wang, T. Colatsky, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR database.

Naomi L Kruhlak, Edwin J Matthews, Joseph F Contrera, 2007, Regulatory toxicology and pharmacology : RTP.

Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses.

Naomi L Kruhlak, Lidiya Stavitskaya, Curran Landry, 2019, Regulatory toxicology and pharmacology : RTP.

Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses

Lidiya Stavitskaya, Raymond Kemper, Glenn J. Myatt, 2018, Regulatory toxicology and pharmacology : RTP.

Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses.

Lidiya Stavitskaya, Raymond Kemper, Alexander Amberg, 2016, Regulatory toxicology and pharmacology : RTP.

Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities.

Naomi L Kruhlak, R Daniel Benz, Edwin J Matthews, 2009, Regulatory toxicology and pharmacology : RTP.

Utilising knowledge relating to 5α-reductase inhibition in the prediction of teratogenicity

N. Kruhlak, M. Surfraz, Alex N. Cayley, 2014 .

Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities.

Naomi L Kruhlak, R Daniel Benz, Gilles Klopman, 2009, Regulatory toxicology and pharmacology : RTP.

Assessing the impact of expert knowledge on ICH M7 (Q)SAR predictions. Is expert review still needed?

Marlene T. Kim, N. Kruhlak, L. Woodard, 2021, Regulatory toxicology and pharmacology : RTP.

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.

Donald P. Quigley, G. Myatt, K. Cross, 2016, Regulatory toxicology and pharmacology : RTP.

Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities.

Naomi L Kruhlak, R Daniel Benz, Edwin J Matthews, 2009, Regulatory toxicology and pharmacology : RTP.